TITLE

Agreements/contracts

PUB. DATE
November 2009
SOURCE
Medical Device Daily;11/6/2009, Vol. 13 Issue 215, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that pharmacogenomic diagnostics provider Sirius Genomics in Vancouver, British Columbia, has signed its first contribution with the National Research Council of Canada Industrial Research Assistance Program. The research funding will be used for the study of genomic correlations in patients with severe sepsis. It is stated that the contribution will go toward the development of Sirius' pharmacogenomic diagnostic for assessing responsiveness to recombinant human activated Protein C in severe sepsis patients at high risk of death.
ACCESSION #
46706349

 

Related Articles

  • Sirius Genomics Launches International Sepsis Study.  // Worldwide Biotech;Nov2011, Vol. 23 Issue 11, p5 

    The article reports on an international sepsis study launched by biotechnology company Sirius Genomics. The stated goal of the study is to find a genetic biomarker for positive response to treatment with activated protein C. Activated protein C offers significant benefit for critical care...

  • Drotrecogin alfa: ongoing safety review.  // WHO Drug Information;2009, Vol. 23 Issue 1, p28 

    The article reports on the study on the safety review for drotrecogin alfa, a recombinant human activated protein C indicated for the reduction of mortality in adult patients with severe sepsis who have a high risk of death, in the U.S. It states that one approach to increasing the safety of...

  • Should Patients at Increased Risk of Bleeding Receive Activated Protein C? Luks, Andrew M. // Critical Care Alert;Mar2009, Vol. 16 Issue 12, p91 

    Synopsis: This retrospective medical record review demonstrated that patients with severe sepsis who received recombinant activated protein C in the face of bleeding precautions had higher rates of bleeding and death compared to those without bleeding precautions.

  • Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis. Manns, B.J.; Lee, H.; Doig, C.J.; Johnson, D.; Donaldson, C.; Wiedemann, Herbert P. // ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p81 

    Summarizes a study that investigated whether treatment with recombinant human-activated protein C is more cost-effective than conventional care for prolonging survival in patients with severe sepsis. Characterization of the patients; Main cost and outcome measures; Results of the study.

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • In Memoriam: Morris Kates (1923-2013). Oren, Aharon; Ventosa, Antonio // Extremophiles;Sep2013, Vol. 17 Issue 5, p699 

    An obituary for Morris Kates, a biochemist who worked for the National Research Council of Canada, is presented.

  • NRC to help Canadian transportation industry reduce vehicle weight.  // MRS Bulletin;Aug2013, Vol. 38 Issue 8, p602 

    The article reports on the establishment of a new program by the National Research Council of Canada (NRC) to help the Canadian transportation industry lessen the weight of trains, buses, trailers, trucks and cars through the development of innovative aluminum technology.

  • IRC becomes "Construction Portfolio".  // Canadian Consulting Engineer;Jun/Jul2013, Vol. 54 Issue 4, p6 

    The article offers information that the Institute for Research in Construction (IRC) of the National Research Council of Canada has become a part of the "Construction Portfolio" of the NRC industry sectors.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics